Authors: Verlinden, L Verstuyf, A Quack, M Van Camp, M Van Etten, E De Clercq, P Vandewalle, M Carlberg, C Bouillon, R

Citation: L. Verlinden et al., Interaction of two novel 14-epivitamin D-3 analogs with vitamin D-3 receptor-retinoid X receptor heterodimers on vitamin D-3 responsive elements, J BONE MIN, 16(4), 2001, pp. 625-638

Authors: Verstuyf, A Segaert, S Verlinden, L Bouillon, R Mathieu, C

Citation: A. Verstuyf et al., Recent developments in the use of vitamin D analogues, EXPERT OP I, 9(3), 2000, pp. 443-455

Authors: Verstuyf, A Verlinden, L Van Etten, E Shi, L Wu, YS D'Halleweyn, C Van Haver, D Zhu, GD Chen, YJ Zhou, XM Haussler, MR De Clercq, P Vandewalle, M Van Baelen, H Mathieu, C Bouillon, R

Citation: A. Verstuyf et al., Biological activity of CD-Ring modified 1 alpha,25-dihydroxyvitamin D Analogues: C-ring and five-membered D-Ring analogues, J BONE MIN, 15(2), 2000, pp. 237-252

Authors: Verlinden, L Verstuyf, A Van Camp, M Marcelis, S Sabbe, K Zhao, XY De Clercq, P Vandewalle, M Bouillon, R

Citation: L. Verlinden et al., Two novel 14-epi-analogues of 1,25-dihydroxyvitamin D-3 inhibit the growthof human breast cancer cells in vitro and in vivo, CANCER RES, 60(10), 2000, pp. 2673-2679

Authors: Verstuyf, A Verlinden, L Segaert, S Van Etten, E Mathieu, C Bouillon, R

Citation: A. Verstuyf et al., Nonclassical effects of 1 alpha,25-dihydroxyvitamin D-3 and its analogs, MIN ELECT M, 25(4-6), 1999, pp. 345-348